文献速递外周动脉疾病

新型自膨式编织镍钛合金支架治疗股腘动脉疾病:单中心首次人体研究12个月结果

Novel Self-Expanding Interwoven Nitinol Stent for Treating Femoropopliteal Artery Disease: 12-Month Results of Single-Center First-in-Man Study.
PubMed 文献 · J Endovasc Ther · 2023-03-16

前瞻性单中心单臂首次人体研究纳入15例股腘动脉病变患者,评估Innospring®支架的安全性和有效性。30天无主要不良事件,6个月和12个月累积一期支架通畅率分别为93.3%和84.6%,13例12个月随访X线片均无支架断裂。结论认为该支架治疗股浅动脉和腘动脉安全有效。

要点

  • 30天主要不良事件发生率为0%,技术和手术成功率100%。
  • 6个月和12个月累积一期支架通畅率分别为93.3%和84.6%。
  • 13例12个月随访X线片确认无支架断裂,Rutherford分级持续改善。

核心结论

  • 使用Innospring®支架治疗股浅动脉和腘动脉安全有效,该竞品编织镍钛合金支架可能提供更优的支架完整性和抗断裂性,并适用于极端机械应力区域。

研究设计与样本

  • 前瞻性、单中心、单臂、首次人体研究,纳入15例患者(平均年龄73.1岁;13例男性),由核心实验室监测评估Innospring®支架的安全性和有效性。

主要发现

  • 病变长度为6.1 ± 3.5 mm,14例(93.3%)患者病变位于股浅动脉,3例(20.0%)患者病变位于腘动脉,9例(60.0%)患者存在中重度钙化病变。
  • 技术和手术成功率为100%,前30天内无患者发生主要不良事件。
  • Rutherford分级在6个月和12个月显示显著且持续的改善。
  • 13例患者12个月随访X线片在100%的检查中确认无支架断裂。
  • 6个月和12个月累积一期支架通畅率分别为93.3%和84.6%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of Innospring® stent, a novel self-expanding interwoven nitinol stent, in treating femoropopliteal atherosclerotic lesions. METHODS: A prospective, single-center, single-arm, first-in-human study enrolled 15 patients (mean age 73.1 years; 13 men) to evaluate the safety and efficacy of the Innospring® stent monitored by core laboratories. The inclusion criteria were claudication or ischemic rest pain, de novo lesions or nonstented restenosis, >70% stenosis, lesion length <20 cm, and a reference vessel diameter of 4-7 mm. The primary safety endpoint was 30-day major adverse events. The primary efficacy end point was stent patency at 12 months. Follow-up evaluations were conducted at 30 days, 6 months, and 12 months. RESULTS: The lesion length was 6.1 ± 3.5 mm. Fourteen (93.3%) patients had lesions of the superficial femoral artery and 3 (20.0%) patients had lesions of the popliteal artery. Nine (60.0%) patients had moderate-to-severe calcified lesion. Technical and procedural success was 100%. No patients experienced major adverse events in the first 30 days. The Rutherford category showed significant and sustained improvement at 6 and 12 months. The 12-month follow-up radiographs obtained in 13 patients confirmed the absence of stent fractures in 100% of examinations. The cumulative primary stent patency rate at 6 and 12 months were 93.3% and 84.6%, respectively. CONCLUSION: Stenting of the superficial femoral and popliteal arteries using the Innospring® stent is safe and effective. This competing interwoven nitinol stent may provide superior stent integrity and fracture-resistance as well as serve areas under extreme mechanical stress. CLINICAL IMPACT: Endovascular recanalization is a widely accepted and recommended treatment for symptomatic peripheral artery diseases. The Innospring® stent is a novel self-expanding interwoven stent containing eight nitinol wires with additional radial force, fracture-resistance, and visibility under fluoroscopy. This first-in-human study using the Innospring® stent in patients with femoropopliteal occlusive disease reported that stenting of the superficial femoral and popliteal arteries using the Innospring® stent is safe and effective. This competing interwoven nitinol stent may provide an impressive stent integrity and fracture-resistance as well as serve areas under extreme mechanical stress.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Yang S, Ni Q, Wang W, et al. Novel Self-Expanding Interwoven Nitinol Stent for Treating Femoropopliteal Artery Disease: 12-Month Results of Single-Center First-in-Man Study. J Endovasc Ther. 2023. PMID: 36927094. doi:10.1177/15266028231159243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。